Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Regeneron Pharmaceuticals Inc — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $76.97, while Regeneron Pharmaceuticals Inc trades at $795.27 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals.
| JPIN | REGN | |
|---|---|---|
52-Week High | $77.00 | $812.27 |
52-Week Low | $64.96 | $555.51 |
Market Cap | — | $82.06B |
Sector | — | Health |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $76.97, up 0.8% on the day, with a bullish technical signal driven by moving averages. The ETF provides broad exposure to foreign large-cap value stocks. Key technical indicators show overbought conditions with RSI levels above 74, while the ADX indicates a strong trend. A dividend of $0.91 per share is scheduled for payment in June 2026.
The outlook for JPIN is supported by its smart beta strategy targeting international value equities, though overbought technicals suggest near-term consolidation risk. Investment appeal lies in diversified global exposure, but risks include currency fluctuations and international market volatility. The absence of current fundamental data limits valuation assessment, requiring reliance on technical and sentiment indicators.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
